A real-world study showed HER2DX guided treatment changes in approximately 48% of HER2-positive breast cancer cases.

is proud to announce the publication of a groundbreaking study demonstrating the clinical impact of HER2DX ®, its genomic diagnostic test designed for early-stage HER2-positive (HER2+) breast cancer.

while this new study establishes the MeCo Score as a predictive biomarker for antifibrotic benefit in HER2-negative breast cancer patients. "In the case of this collaboration with our colleagues ...